gemcitabine, oxaliplatin

Phase 3Small molecule

AstraZeneca

gemcitabine, oxaliplatin is one of 98 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaUnknown status

Biliary Tract CancerActive, not recruiting

LymphomaPhase 2

Unknown status

Biliary Tract CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Lymphoma

#DrugCompanyPhaseTrials

gemcitabine, oxaliplatin

AstraZeneca

Phase 3

2 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Intrahepatic Cholangiocarcinoma (icc)

NCT07847710

Q4 2030

Phase 2Not yet recruiting

Lymphoma

NCT07711483

Clinical

Trials by Indication[1]

Lymphoma2 trials

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04948788·102 enrolled

Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

Not yet recruiting·MMassachusetts General Hospital·Phase 2·NCT07711483·56 enrolled

Pancreatic Cancer1 trial

A Study of Locally Advanced Pancreatic Cancer

Unknown status·NNational Health Research Institutes, Taiwan·Phase 2·NCT01063192·73 enrolled

Gemcitabine1 trial

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00127595·28 enrolled

Hepatocellular Carcinoma1 trial

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

Completed·YYonsei University·Phase 2·NCT05517239·32 enrolled

Locally Advanced1 trial

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT01267344·122 enrolled

3 more indications

Intrahepatic Cholangiocarcinoma (Icc)1 trial

Perioperative Retlirafusp Alfa（Anti-PD-L1/TGF-β Bifunctional Fusion Protein） Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial: H-FROG Feasibility Study

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07847710·81 enrolled

Biliary Tract Neoplasms1 trial

Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study

Completed·33D Medicines (Sichuan) Co., Ltd.·Phase 3·NCT03478488·472 enrolled

Biliary Tract Cancer1 trial

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05771480·142 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for gemcitabine, oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine, oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine, oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

gemcitabine, oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2030

Trials by Indication[1]

Lymphoma2 trials

Pancreatic Cancer1 trial

Gemcitabine1 trial

Hepatocellular Carcinoma1 trial

Locally Advanced1 trial

Intrahepatic Cholangiocarcinoma (Icc)1 trial

Biliary Tract Neoplasms1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News